TNF-α inhibitors are a class of therapeutic agents designed to block the action of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in various autoimmune diseases and inflammatory conditions. The substance with CAS number 1049741-03-8 is a specific TNF-α inhibitor that functions by binding to TNF-α, preventing it from interacting with its receptors, thereby reducing inflammation and modulating immune responses. These inhibitors are commonly used in the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. Characteristically, TNF-α inhibitors can be monoclonal antibodies or small molecules, and they often exhibit high specificity for TNF-α, leading to a reduction in the associated inflammatory pathways. The pharmacokinetics of these inhibitors typically involve considerations of absorption, distribution, metabolism, and excretion, which can vary based on the specific formulation. Safety profiles may include risks of infections and other immune-related effects, necessitating careful monitoring during treatment. Overall, TNF-α inhibitors represent a significant advancement in the management of chronic inflammatory diseases.

TNF-α inhibitor

1049741-03-8: TNF-α inhibitors are a class of therapeutic agents designed to block the action of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in various autoimmune diseases and inflammatory conditions. The substance with CAS number 1049741-03-8 is a specific TNF-α inhibitor that functions by binding to TNF-α, preventing it from interacting with its receptors, thereby reducing inflammation and modulating immune responses. These inhibitors are commonly used in the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. Characteristically, TNF-α inhibitors can be monoclonal antibodies or small molecules, and they often exhibit high specificity for TNF-α, leading to a reduction in the associated inflammatory pathways. The pharmacokinetics of these inhibitors typically involve considerations of absorption, distribution, metabolism, and excretion, which can vary based on the specific formulation. Safety profiles may include risks of infections and other immune-related effects, necessitating careful monitoring during treatment. Overall, TNF-α inhibitors represent a significant advancement in the management of chronic inflammatory diseases.

SPD304 (dihydrochloride)

<p>SPD304 dihydrochloride is a selective inhibitor of TNF-α with an IC50 of 22 µM. SPD304 dihydrochloride promotes dissociation of TNF trimers.</p>

CAS 1049741-03-8

TNF-α inhibitor

SPD304 (dihydrochloride)

Ref: IN-DA01DZGF

SPD304 dihydrochloride

Ref: TM-T12985